Natco Pharma Increases Investment in eGenesis to US$16.70 Million
Natco Pharma Ltd 路 Press Release 路 28 Sept 2026, 8:28 pm
Natco Pharma Increases Investment in eGenesis to US$16.70 Million Natco Pharma has increased its planned investment in US-based biotechnology firm eGenesis, Inc. from US$14.00 million to US$16.70 million via convertible promissory notes carrying an 8% annual interest rate. The transaction comprises US$13.70 million via Natco Pharma (Canada) Inc. and US$3.00 million via Natco Pharma USA LLC, with completion targeted by 31st Oct'26. Following an earlier US$8.00 million investment in 2024, Natco's total commitment will rise to US$24.70 million, backing eGenesis's multiplex gene-editing platform for cross-species organ transplantation.
Original exchange filing (PDF)
More announcements from Natco Pharma Ltd
- Intimation of Investor Meet 路 17 Nov 2026
- Audio link of Earnings Conference Call Q2FY27 路 14 Nov 2026
- Q2 FY27 Earnings Presentation 路 13 Nov 2026
- Un audited Financial Results for the quarter and half year ended 30th September, 2026 路 13 Nov 2026
- 19th November, 2026 is the Record Date for the payment of 2nd Interim Dividend for FY 2026-27 路 13 Nov 2026
- Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026 and declaration of 2nd Interim Dividend for FY 2026-27 路 13 Nov 2026
- Outcome of Board Meeting 路 13 Nov 2026
- Intimation of schedule of Concall 路 13 Nov 2026
